| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Strengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer |
| 15 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
NEW YORK, September 15, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the mu... |
| 03 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the mul... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 |
| 29 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 28, 2026, by and among LB Pharmaceuticals Inc, a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (eac... |
| 22 Jul 2026 |
8-K: Other Events
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia |
| 10 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This letter sets forth the substance of the separation agreement (the “Agreement”), by and between LB Pharmaceuticals Inc (the “Company”) and you, which confirms our mutual agreement to end your employment with the Company and sets forth... |
| 09 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
LB Pharmaceuticals Inc (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 3, 2026, at which a quorum was present. The final results for each of the proposals submitted to a vote of the Company’s s... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
Reported positive results from potentially registrational Phase 2 trial of |
| 16 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 10 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development |
| 05 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 4, 2026, by and among LB Pharmaceuticals Inc, a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (... |
| 13 Nov 2025 |
8-K: Entry into a Material Definitive Agreement
THIS FIRST AMENDMENT OF LEASE (this “Amendment”), made as of the 10th day of November 2025, by and between ONE PENN PLAZA LLC, a New York limited liability company, having an office at c/o Vornado Office Management LLC, 888 Seventh Avenu... |
| 12 Nov 2025 |
8-K: Other Events
NEW YORK, NY, November 12, 2025 (GLOBE NEWSWIRE) — LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depressio... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
NEW YORK, November 6, 2025 (GLOBE NEWSWIRE) – LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced financial results for the third quarter ended on September 30, 2025 and provided recent corporate... |
| 12 Sep 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
LB Pharmaceuticals Inc, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: |
Loading...